## National Diabetes Inpatient Safety Audit 2018-2021 England and Wales 14 July 2022

# An annual survey of GIRFT recommended staffing, systems and pathways

**Results and findings** 

## Contents



	Section	Slide
1	Executive summary	<u>3</u>
2	Introduction	<u>10</u>
3	Inpatient service provision	<u>12</u>
4	Inpatient harms: Trends	<u>18</u>
5	Inpatient harms: Patient profiles	<u>24</u>
6	Further information	<u>31</u>

#### Key details:

This report covers:

a) the provision of inpatient services in England and Wales on 1 October 2021; and

b) diabetes-specific inpatient harms in England between 1 May 2018 and 31 October 2021.

**Acronyms:** The following acronyms and abbreviations are used throughout the report:

- **BG** = Blood glucose
- **DKA** = Diabetic ketoacidosis
- **DFU** = Diabetic foot ulcer
- **eGFR** = Estimated glomerular filtration rate
- **GIRFT** = Getting It Right First Time
- **HES** = Hospital Episode Statistics
- **HHS** = Hyperosmolar hyperglycaemic state
- **ISS** = Integrated Specialist Services Structures Survey
- LHB = Local health board
- **LOS** = Length of stay
- **MDiT** = Multi-disciplinary diabetes inpatient team
- **NaDIA** = National Diabetes Inpatient Audit
- NDISA = National Diabetes Inpatient Safety Audit
- **NDA** = National Diabetes Audit
- **NICE** = The National Institute for Health and Care Excellence

**RRT** = Renal replacement therapy

## National Diabetes Inpatient Safety Audit: 2018-21

## **1. Executive summary**

## **1. Executive summary:**

## Key findings: Inpatient service provision


The National Diabetes Inpatient Safety Audit (NDISA) reviewed inpatient service provision in England and Wales against the 2020 Diabetes Getting It Right First Time (<u>GIRFT</u>) recommendations.

6 inpatient-specific GIRFT recommendations were assessed for this report. The proportion of healthcare providers meeting each GIRFT recommendation can be seen in Chart 1.1 (right).

### Findings: Service coverage ranged from:

- 72% of healthcare providers providing insulin training for appropriate staff [GIRFT recommendation 8]; and 72% having a selfmanagement policy [GIRFT recommendation 10]; to
- Only **27%** of providers having a system to identify people with diabetes on admission, prioritising those at highest risk, involving networked blood glucose (BG) meters [GIRFT recommendation 7]

**Chart 1.1:** Percentage of responders that fully met each GIRFT recommendation<sup>1</sup>, England and Wales, October 2021



**GIRFT recommendations**: The full text of each GIRFT recommendation is on the associated slide later in the report. Brief descriptions of the GIRFT recommendations are below: **5**. Dedicated multi-disciplinary inpatient diabetes teams (MDiTs): provision and weekend cover (actual or planned) (<u>slide 14</u>). **6**. Dedicated MDiTs: meeting and reporting (<u>slide 15</u>). **7**. Identifying diabetes on admission and ensuring rapid referral (<u>slide 16</u>). **8** Reducing insulin errors (<u>slide 17</u>). **9**. Improving care through perioperative pathways (<u>slide 17</u>). **10**. Supporting self-management in hospital (<u>slide 17</u>).


## **1. Executive summary:** Key findings: Inpatient harms

NDISA has reviewed the rate of 4 life-threatening diabetes-specific inpatient harms that occurred due to errors of inpatient diabetes management in England between Q1 2019 (Jan-Mar) and Q3 2021 (Jul-Sep): inpatient onset of hypoglycaemia requiring rescue, diabetic ketoacidosis (DKA), hyperosmolar hyperglycaemic state (HHS) and diabetic foot ulcer (DFU).

**Findings:** The rate of total inpatient harms decreased by almost 40% from 26.3 per 100,000 occupied bed days in Q1 2019 (Jan-Mar) to 16.2 in Q3 2021 (Jul-Sep) (see <u>Chart 4.2</u>). Chart 1.2 (right) shows that this trend is largely driven by reductions in hypoglycaemic rescue (from 18.9 to 11.1), which comprise 69% of total inpatient harms. There was also a small peak in Q2 2020 (Apr-Jun) of 15.2, coinciding with wave 1 of the COVID-19 pandemic.

Although the DFU rate follows a similar downward trend (3.2 to 1.4), there was no apparent reduction in the rate of inpatient DKA or HHS.

**Chart 1.2:** Inpatients with diabetes, by quarter: rate of inpatient harms: hypoglycaemic rescue, DKA, DFU and HHS, England, January 2019 - September 2021 (rounded<sup>1</sup>)




**Notes: 1**. Proportions are derived from rounded values. Underlying counts between 1 and 7 are set to 5. All counts greater than 7 are rounded to the nearest 5

# **1. Executive summary:** NDISA recommendations (1)

NDISA recommendation 1: All NHS Trusts in England and LHBs (Local Health Boards) in Wales should participate in NDISA data collection.

**Why?** NDISA is a mandatory national audit. Participating in data collection allows healthcare providers to check compliance with GIRFT recommendations, to monitor adverse inpatient diabetes outcomes and to benchmark against their peers. This allows them to understand their current position and identify areas for improvement.

What the audit tells us: Of 126 organisations eligible for NDISA, 85 (67%) responded to the specialist services structures survey and 109 (87%) have at some time submitted harms data with 63 (50%) submitting data regularly.



# **1. Executive summary:** NDISA recommendations (2)

NDISA recommendation 2: Healthcare providers, NHS trusts in England and LHBs in Wales, should have a multidisciplinary diabetes inpatient team (MDiT) and be working towards providing base-level diabetes cover at weekends.



**Why?** The MDiT plays a central role in providing safe, effective inpatient diabetes care. For this reason, the NHS Long Term Plan (3.81), the 2019 National Diabetes Inpatient Audit (NaDIA) <u>report</u> (recommendation 3) and the 2020 GIRFT <u>report</u> (recommendation 5) have all previously made this recommendation.


What the audit tells us: 13% of healthcare providers still do not have an MDiT in spite of these recommendations (see <u>Table 3.2</u>). Only 32% of healthcare providers currently have both an MDiT in place and provide cover at weekends, a further 27% have an MDiT in place and are working towards weekend cover (<u>Table 3.2</u>).

# **1. Executive summary:** NDISA recommendations (3)

NDISA recommendation 3: Healthcare providers should have networked BG meters to alert staff when recorded glucose levels are out-of-range (increased risk).

**Why?** Networked BG meters can alert the MDiT to high and low BG readings when they occur, directing support to those most in need. They also allow audit and review of glucose readings, permitting ongoing review of the overall safety and effectiveness of inpatient diabetes care. This supports <u>GIRFT</u> recommendation 7.

What the audit tells us: Only 56% of healthcare providers have networked BG meters with a system to alert the diabetes team to out-of-range BG values (see <u>Table 3.4</u>).



## **1. Executive summary:** NDISA recommendations (4)

NDISA recommendation 4: All participating organisations should have a policy to support diabetes self-management in hospital.

**Why?** 17% of inpatients are people with diabetes. They are experts in self-management and often feel unsafe when handing over their diabetes management to others in hospital. The issue has been highlighted as of particular importance by people living with diabetes who are part of the NDISA advisory group.

What the audit tells us: 72% of responding organisations report having a self-management policy. For people with diabetes, it is a priority that these policies become universal and that they are promoted in line with <u>GIRFT</u> recommendation 10.



## National Diabetes Inpatient Safety Audit: 2018-21

## 2. Introduction

## **2. Introduction:** Overview

This is the 1st National Diabetes Inpatient Safety Audit (NDISA) report. NDISA has 2 core components:

- A review of **inpatient service provision** in England and Wales, using the 1) National Diabetes Audit (NDA) Integrated Specialist Services Structures Survey (ISSSS, abbreviated to ISS) undertaken in October 2021. Service provision is assessed against recommendations in the 2020 Diabetes Getting It Right First Time (GIRFT) report.
- A review of the rates and risk factors for serious diabetes-specific 2) inpatient harms in England only, using the NDISA harms collection, a mandatory year-round collection of 4 harms that can occur to inpatients with diabetes in acute hospitals in England. The data collection started on 1 May 2018. The collection was previously known as National Diabetes Inpatient Audit (NaDIA) – Harms.

NDISA is part of the NDA programme within the National Clinical Audit and Patient Outcomes Programme (NCAPOP), commissioned by the Healthcare Quality Improvement Partnership (HQIP) on behalf of NHS England and the Welsh Government.

Prepared in collaboration with:







11

Supported by:



## National Diabetes Inpatient Safety Audit: 2018-21

## 3. Inpatient service provision

# **3. Inpatient service provision:** Background

The National Diabetes Inpatient Safety Audit (NDISA) looked at the provision of inpatient services using the Integrated Specialist Services Structures Survey (ISSSS, abbreviated to ISS), a National Diabetes Audit (NDA) questionnaire which asks healthcare providers whether they have put in place structures and systems of care for people with diabetes recommended by the Getting It Right First Time (<u>GIRFT</u>) programme. The ISS was distributed to healthcare providers in England and Wales in October 2021.

The inpatient section of the ISS is comprised of questions on 17 aspects of inpatient care delivery identified as important by the 2018 Diabetes UK <u>report</u>: Making Hospitals Safe for People with Diabetes. The results of 11 of the 17 ISS questions are included in this report, relating to 6 GIRFT recommendations.

#### **Participation in ISS**

96 providers responded to the ISS (see Table 3.1, right). This report includes data from the 85 ISS responders which provide acute inpatient medical care<sup>1</sup>: 82 NHS trusts in England and 3 local health boards in Wales (LHBs). There are 138 acute providers in England<sup>2</sup> and 7 in Wales<sup>3</sup>, so the overall ISS response rate is 59% (85 of 145). Data from all 96 responders is provided in supporting documentation.

Table 3.1: Submitters to the ISS,

England and Wales, October 2021

Provider type	Total
Acute NHS trust	82
Other NHS trust	10
LHB	3
Independent healthcare provider	1
Total	96

## 3. Inpatient service provision: **GIRFT** recommendation 5: MDiT provision and cover

#### **GIRFT recommendation 5:**

All healthcare providers must have a dedicated multi-disciplinary team of specialist diabetes inpatient practitioners (MDiTs) as indicated in the NHS Long Term Plan (3.81). Healthcare providers should work towards providing base level specialist diabetes cover at weekends where this does not exist.

### Table 3.2: Proportion of healthcare providers meeting GIRFT recommendation 5:

Dedicated MDiTs: provision and weekend cover (actual or planned), England and Wales, October 2021

### **Findings**

Table 3.2 (left) shows that:

- **32%** (27 of 85 responders) had an MDiT team and already provide diabetes cover on weekends.
- A further **27%** (23 of 85) had an MDiT team and are planning to provide diabetes cover on weekends, making **59%** (50 of 85) in total. 14

Question	Answered Yes
a) Does the provider have a dedicated multi-disciplinary team of specialist diabetes inpatient practitioners?	<b>87%</b> (74 of 85)
b) Is the provider providing base level specialist diabetes cover at weekends?	<b>32%</b> (27 of 85)
c) Is the provider working towards providing base level specialist diabetes cover at weekends?	<b>27%</b> (23 of 85)
Meeting GIRFT recommendation 5 (a and b or c)	<b>59%</b> (50 of 85)

# **3. Inpatient service provision:** GIRFT recommendation 6: MDiT meeting and reporting

#### **<u>GIRFT</u>** recommendation 6:

The MDiT should meet regularly to discuss day-to-day errors and safety issues, and report to a quarterly provider-level diabetes safety board which reviews the overall quality of the inpatient service, with support from IT, based on incident reporting, local and national audits of patient harms, diabetes medication errors, length of stay and readmissions.

#### Table 3.3: Proportion of healthcare providers meeting GIRFT recommendation 6:

Dedicated MDiTs: meeting and reporting, England and Wales, October 2021

Question	Answered Yes
a) Does the provider MDiT meet regularly to discuss day-to- day errors and safety issues?	<b>79%</b> (67 of 85)
b) Does the provider MDiT report to a quarterly trust-level diabetes safety board which reviews the overall quality of the inpatient service?	<b>45%</b> (38 of 85)
Meeting GIRFT recommendation 6 (both a and b)	44% (37 of 85)

### **Findings**

Table 3.3 (left) shows that:

 44% (37 of 85) of responders fully met GIRFT recommendation 6.

# **3. Inpatient service provision:** GIRFT recommendation 7: Admission and rapid referral

**<u>GIRFT</u>** recommendation 7: All healthcare providers should have a robust system to identify all people with diabetes on admission to hospital, including emergencies and elective and non-elective surgery, and a triage system to identify those at risk and rapidly refer them to the diabetes team. This should be an electronic system, integrated with web-linked blood glucose (BG) meters which provide an alert system for staff when any out-of-range reading is recorded.

 Table 3.4: Proportion of healthcare providers meeting GIRFT recommendation 7:

 Identifying diabetes on admission and ensuring rapid referral, England and Wales, October 2021

Question	Answered Yes
a) Does the provider have a robust system to identify all people with diabetes on admission to hospital, including emergencies and elective and non-elective surgery?	<b>51%</b> (43 of 85)
b) Does the provider have a triage system to identify those at risk and rapidly refer them to the diabetes team?	<b>71%</b> (60 of 85)
c) Does the provider have an electronic system, integrated with web-linked BG meters which provides an alert system for staff when any out-of-range reading is recorded?	<b>56%</b> (48 of 85)
Meeting GIRFT recommendation 7 (a, b and c)	27% (23 of 85)

### Findings

Table 3.4 (left) shows that:

• 27% (23 of 85) of responders fully met GIRFT recommendation 7.

# **3. Inpatient service provision:** GIRFT recommendations 8, 9 and 10

#### Table 3.5: Proportion of healthcare providers meeting GIRFT recommendations 8, 9 and 10:

Reducing insulin errors, improving care through perioperative pathways and supporting self-management in hospital, England and Wales, October 2021

Question	Answered Yes
<b>GIRFT recommendation 8:</b> <b>Reducing insulin errors</b> : Training should be provided for every healthcare professional who dispenses, prescribes and/or administers insulin, appropriate to their level of responsibility, including an assessment of competency.	<b>72%</b> (61 of 85)
<b>GIRFT recommendation 9:</b> <b>Improving care through perioperative pathways</b> : All hospital trusts should have clear, audited perioperative pathways from pre-assessment through to discharge. These should be broadly in line with National Confidential Enquiry into Patient Outcome and Death ( <u>NCEPOD</u> ) recommendations.	<b>64%</b> (54 of 85)
<b>GIRFT recommendation 10:</b> <b>Supporting self-management in hospital</b> : All trusts should have and promote a self- management policy, which supports patients who want to self-manage their diabetes to safely do so while in hospital, as clinically appropriate and in line with wider NHS England (NHSE) and NHS Improvement (NHSI) policies on inpatient self-management (e.g. NHS Long Term Plan (3.79).	<b>72%</b> (61 of 85)

## National Diabetes Inpatient Safety Audit: 2018-21

## 4. Inpatient harms: Trends

## **4. Inpatient harms: Trends** The NDISA harms collection

The National Diabetes Inpatient Safety Audit (NDISA) undertakes a continuous collection of 4 life-threatening diabetesspecific inpatient harms that occur due to errors of inpatient diabetes management. These events are distressing, slowdown recovery, may be life-threatening and should be preventable. The collection started on 1 May 2018 and was previously known as the National Diabetes Inpatient Audit (NaDIA) – <u>Harms</u>.

**Hypoglycaemic rescue**: A hypoglycaemic episode is a potentially dangerous drop in a patient's blood glucose (BG) to below 4.0 mmol/L. Severe hypoglycaemia requires **rescue treatment** because the patient is either unconscious, too confused to follow instruction or unable to swallow safely. Rescue treatment is applied using an injection of glucose or glucagon.

**Diabetic ketoacidosis (DKA)**: DKA occurs (mainly in people with type 1 diabetes) when a severe lack of insulin means the body cannot use glucose for energy and the body starts to break down other body tissue, releasing ketones as an alternative energy source. This can lead to life threatening ketoacidosis if the levels are too high.

**Hyperosmolar hyperglycaemic state (HHS)**: HHS mainly occurs in people with type 2 diabetes who experience very high BG levels (often over 40mmol/L). It can develop over a course of days or weeks through a combination of illness (e.g. infection) and dehydration, and following high dose steroid therapy.

**Diabetic foot ulcer (DFU)**: Patients with diabetes are at a higher risk of developing foot lesions (ulcers) if they have diabetes associated blood flow (ischaemia) and nerve problems (neuropathy).

A hospital inpatient whose BG levels are optimally managed should only very rarely experience a severe hypoglycaemic episode requiring rescue treatment.

The development of DKA after admission suggests that the person's insulin treatment was omitted, or insufficient levels of insulin were provided, for an appreciable time. DKA is a potentially life-threatening emergency which should not develop in hospital.

> HHS is a potentially life-threatening emergency which should not develop in hospital.

Preventive care should stop new foot lesions developing in hospital.


## **4. Inpatient harms: Trends** Participation

NHS trusts in England are known to be eligible<sup>1</sup> for the NDISA harms collection

126


It is a mandatory requirement for acute hospitals in England to participate in the NDISA harms collection. Based on the numbers of NHS trusts known to be eligible<sup>1</sup>, participation<sup>2</sup> in the NDISA harms collection is presently 87% (109 of 126), with 58% (63 of 109) participating regularly<sup>3</sup>. There have been 6 new participants<sup>2</sup> in the preceding year (November 2020 to October 2021).

In the upcoming year (2022), the NDISA team will start contacting nonparticipating NHS trusts to ask them why they have not taken part, and to suggest that they offer support to diabetes teams to enable them to submit data.



## **4. Inpatient harms: Trends** Frequency of inpatient harms by type

Chart 4.1: Number of inpatient harms, by harm type, England, May 2018 - October 2021 (rounded<sup>1</sup>)




#### Table 4.1: Number of inpatient harms, by harm type and quarter when inpatient harm occurred, England, May 2018 - October 2021 (rounded<sup>1</sup>)

Inpatient harm	May – Jul 18		Nov 18 – Jan 19												Total
Hypoglycaemic rescue	210	335	455	440	360	310	325	305	245	270	260	230	275	230	4,255
DKA	50	85	80	80	70	80	90	75	65	65	90	55	80	85	1,060
HHS	5	15	25	15	15	10	10	15	10	15	20	15	10	10	190
DFU	60	50	65	75	55	65	45	40	40	35	30	25	40	20	645
Total	325	485	625	615	500	465	475	435	360	385	400	325	405	345	6,150

**Notes: 1**. Counts have been rounded. Counts between 1 and 7 are represented as a 5. All counts greater than 7 have been rounded to the nearest 5. Consequently the total will not usually match the sum of the 4 constituent inpatient harms.

# **4. Inpatient harms:** Rate of inpatient harms by quarter: Hypoglycaemic rescue

Chart 4.2: Inpatients with diabetes, by quarter: rate of all inpatient harms and hypoglycaemic rescue<sup>2,3</sup>, England, January 2019 - September 2021 (rounded<sup>1</sup>)



#### Findings:

Chart 4.2 (left) shows that the rate of total inpatient harms decreased by almost 40% from Q1 2019 (Jan-Mar) to Q3 2021 (Jul-Sep).


The decrease is largely driven by reductions in hypoglycaemic rescue, which comprise 69% of total inpatient harms. This trend tallies with the findings from the final NaDIA report (NaDIA 2019, Chart 2.2).

**Notes: 1**. Proportions and rates are derived from rounded values. Underlying counts between 1 and 7 are set to 5. All counts greater than 7 are rounded to the nearest 5. **2**. Analysis covering April-Oct 2021 uses provisional data from Hospital Episode Statistics (<u>HES</u>) and core National Diabetes Audit (<u>NDA</u>). **3**. Proportions and rates are calculated from the sum of nights in hospital during the period stated for people in the core NDA, where diabetes was diagnosed on or before admission. Day cases and same-day discharges are counted as zero days and are therefore excluded. For further information, see: <u>Further information</u>: <u>Inpatient population with diabetes</u>.

# **4. Inpatient harms:** Rate of inpatient harms by quarter: DKA, DFU and HHS

Chart 4.3: Inpatients with diabetes, by quarter: rate of DKA, DFU and HHS<sup>2,3</sup>,

England, January 2019 - September 2021 (rounded<sup>1</sup>)



### **Findings**

Chart 4.3 (left) shows that, although the rate of DFUs appears to follow a downward trend, there was no reduction in the rate of DKA and HHS. This also tallies with the findings from the final NaDIA report (NaDIA 2019, Charts 2.3-2.5).

**Notes: 1**. Proportions and rates are derived from rounded values. Underlying counts between 1 and 7 are set to 5. All counts greater than 7 are rounded to the nearest 5. **2**. Analysis covering April-Oct 2021 uses provisional data from <u>HES</u> and <u>core NDA</u>. **3**. Proportions and rates are calculated from the sum of nights in hospital during the period stated for people in the core NDA, where diabetes was diagnosed on or before admission. Day cases and same-day discharges are counted as zero days and are therefore excluded. For further information, see: <u>Further information</u>: <u>Inpatient population with diabetes</u>.

## National Diabetes Inpatient Safety Audit: 2018-21

## 5. Inpatient harms: Patient profiles

## **5. Inpatient harms: Patient profiles** Background

This section of the report looks at characteristics associated with a greater risk of the 4 inpatient harms collected by the National Diabetes Inpatient Safety Audit (NDISA), with the aim of better understanding high-risk features which might help target preventive care.

The hospital admission characteristics of people with diabetes are identified in the Hospital Episode Statistics (<u>HES</u>). Patient demographics, diabetes characteristics, treatment targets and care processes are linked from the core National Diabetes Audit (<u>NDA</u>).

Data from the NDISA harms collection is used to identify hospital bed days where 1 of the following inpatient harms occurred: hypoglycaemic rescue, diabetic ketoacidosis (DKA), hyperosmolar hyperglycaemic state (HHS) and diabetic foot ulcer (DFU). A baseline population of inpatients with diabetes is created for comparison, excluding bed days where an inpatient harm occurred.

To adjust for length of stay, figures are based on occupied bed days. For example, a hospital stay lasting 1 night counts as 1 occupied bed day, 5 nights counts as 5 occupied bed days etc. The statistical significance of differences between occupied bed days where a harm occurred versus the bulk of days where a harm did not occur was assessed at the 95% level.

### **Findings:**

Overall, those experiencing inpatient harms are more likely to:

- Have been admitted as an emergency (see <u>Table 5.4</u>).
- Have type 1 diabetes (<u>Table 5.2</u>).
- Have <u>not</u> received 8 care processes in the last 12 months (<u>Table 5.3</u>).
- Have <u>not</u> met the HbA1c treatment target (<u>Table 5.3</u>).
- Experience cardiovascular or diabetesspecific complications on admission or during their hospital stay (<u>Table 5.5</u>). In particular, inpatients having strokes on or during admission are more likely to experience HHS during their hospital stay.

## **5. Inpatient harms: Patient profiles** Summary

Table 5.1: Summary of characteristics associated with each inpatient harm compared to the whole inpatient population with diabetes<sup>1</sup>, England, May 2018 - October 2021

			Inpatier	nt harm	
C	Characteristic	Hypoglycaemic rescue	DKA	HHS	DFU
	Age	Younger	Younger	Older	None
	Sex	None	Female	Male	Male
Demo-	Ethnicity	White	White	None	White
graphics	Smoking status <sup>2</sup>	Current	Current	None	None
	Deprivation quintile	Least	Least	None	None
	BMI	Lower	Lower	Lower	None
Diabetes	Diabetes type	Type 1	Type 1	Type 1	Type 1
charact-	Diabetes duration	Longer	Longer	Longer	Longer
eristics	Renal function	Worse	Better	None	Worse
	Blood pressure (≤ 140/80)	None	None	None	None
Treatment	Cholesterol (< 5 mmol/L)	Not met	Not met	None	None
targets and care	HbA1c (≤ 58 mmol/mol)	Not met	Not met	Not met	Not met
processes <sup>3</sup>	Met 3 treatment targets?	No	No	No	No
	Had all 8 care processes?	No	No	None	No
Hospital	Admission method <sup>4</sup>	Emergency	Emergency	Emergency	Emergency
admissions	Admission type	Medical	Surgical	Medical	Surgical
Complications during admission <sup>5</sup>		Heart failure, Admitted for DKA, Admitted with diabetic foot disease, Renal replacement therapy (RRT) required during admission	Angina, Heart failure, Admitted for DKA, RRT required during admission	Stroke, Admitted for DKA, Admitted with diabetic foot disease	Heart failure, Admitted for DKA, Admitted with diabetic foot disease, RRT required during admission

Table 5.1 (left) compares the group characteristics for each inpatient harm against those of the whole **inpatient population with diabetes**. For example, we can see that the group experiencing inpatient DKA tend to be younger than the wider inpatient population with diabetes.

Different results would be found if comparing inpatient harms against a different population. For example, DKA and hypoglycaemic rescue would almost certainly be associated with higher (not lower) deprivation if compared to the England and Wales population.

Notes: 1. Statistical significance of harms population vs. inpatient population with diabetes at the 95% level. Proportions are tested using the Chi-squared test. Medians are tested using the Mann–Whitney U test. 2. Group comprises of nonsmokers whose history is unknown and patients who have never smoked. 3. See note 4 on <u>slide 28</u>. 4. See note 4 on <u>slide 29</u>. 26 5. See note 4 on <u>slide 30</u>.

# **5. Inpatient harms: Patient profiles** Diabetes characteristics

#### Table 5.2: Diabetes characteristics, by inpatient harm<sup>2</sup>,

England, May 2018 - October 2021 (rounded<sup>1</sup>)

Group	Diabe	tes type	e	Diabete duratio		Renal function (Estimated glomerular filtration rate – eGFR) (ml/min/1.73m <sup>2</sup> )		
	Type 1	Type 2		Median		Median		
	%	%		meanan		Wedian		
Inpatient population with diabetes	7.7	92.3		12.0		67.7		
Hypoglycaemic rescue	34.1	65.9	*	19.0	*	58.8 <mark>*</mark>		
• DKA	63.5	36.5	*	21.0	*	77.2 *		
• HHS	13.9	86.1	*	16.0	*	66.8 <mark>n</mark>		
Inpatient population with diabetes <sup>3</sup> (Length of stay – LOS≥3)	7.5	92.5		12.0		67.2		
• DFU (LOS≥3)	14.3	86.6	*	16.0	*	58.2 <mark>*</mark>		

### **Findings**

Table 5.2 (left) shows that higher risk characteristics for inpatient harms include:

- Diabetes type 1
- Longer diabetes duration
- Impaired renal function (except DKA and HHS)

**Notes**: \* = statistically significant at the 0.05 level vs. inpatient population. n = not statistically significant. Proportions are tested using the Chi-squared test. Medians are tested using the Mann–Whitney U test. Cases with missing or unknown values are excluded from the calculations. The proportions of the inpatient population (data row 1, all diabetes) with missing or unknown values are: Diabetes type 3.5%; Diabetes duration 1.9%; eGFR 13.2%. **1**. Percentages are derived from rounded values. Underlying counts between 1 and 7 are set to 5. All counts greater than 7 are rounded to the nearest 5. Consequently some percentages may not sum up to exactly 100%. **2**. Proportions are calculated from the sum of nights in hospital during the period stated for people in the core NDA, where diabetes was diagnosed on or before admission. Day cases and same-day discharges are counted as zero days and are therefore excluded. For further information, see: <u>Further information: Inpatient population with diabetes</u>. **3**. See note 2 above, with additional exclusion for admissions that are less than 3 nights due to the audit requirement that new onset foot ulcers must occur more than 72 hours after admission.

## **5. Inpatient harms: Patient profiles** Treatment targets and care processes

Table 5.3: Treatment targets and care processes in the audit year preceding hospital admission<sup>4</sup>,

by inpatient harm<sup>2</sup>, England, May 2018 - October 2021 (rounded<sup>1</sup>)

	Trea	atr	Received all 8 care						
Group	Blood pressure (≤ 140/80)		Cholesterol (< 5 mmol/L)		HbA1c (≤ 58 mmol/mol)		Met all 3 treatmen targets		processes <sup>4</sup> in year prior to admission
	%		%		%		%		%
Inpatient population with diabetes	67.6		67.7		56.3		31.4		43.5
Hypoglycaemic rescue	68.1	n	64.2	*	26.0	*	14.6	*	37.8 <mark>*</mark>
• DKA	67.0	n	56.3	*	14.2	*	7.1	*	37.6 *
• HHS	68.8	n	68.8	n	34.4	*	18.8	*	40.6 <mark>n</mark>
Inpatient population with diabetes <sup>3</sup> (LOS≥3)	67.5		67.7		56.3		31.4		43.0
• DFU (LOS≥3)	65.5	n	67.3	n	44.2	*	22.1	*	36.3 <mark>*</mark>

**Findings:** Table 5.3 (left) shows that higher risk characteristics for inpatient harms include:

- Higher HbA1c in the audit year prior to admission
- Not having all 8 care processes in the audit year prior to admission (except HHS)

The low proportion for each harm not meeting all 3 treatment targets is primarily driven by those missing the HbA1c target.

**Notes**: \* = statistically significant at the 0.05 level vs. inpatient population. n = not statistically significant. Proportions are tested using the Chi-squared test. Cases with missing or unknown values are excluded from the calculations. The proportions of the inpatient population (data row 1, all diabetes) with missing or unknown values are: 8.6-8.7% (all variables). **1**. Percentages are derived from rounded values. Underlying counts between 1 and 7 are set to 5. All counts greater than 7 are rounded to the nearest 5. Consequently some percentages may not sum up to exactly 100%. **2**. Proportions are calculated from the sum of nights in hospital during the period stated for people in the <u>core NDA</u>, where diabetes was diagnosed on or before admission. Day cases and same-day discharges are counted as zero days and are therefore excluded. For further information, see: <u>Further information</u>: <u>Inpatient population with diabetes</u>. **3**. See note 2 above, with additional exclusion for admissions that are less than 3 nights due to the audit requirement that new onset foot ulcers must occur more than 72 hours after admission. **4**. Treatment target and care process information was taken from the core NDA audit year prior to the hospital admission (e.g. from 2017-18 where the person's hospital admission was in 2018-19).

## **5. Inpatient harms: Patient profiles** Hospital admissions

Table 5.4: Hospital admission method and main specialty, by inpatient harm<sup>2</sup>,

England, May 2018 - October 2021 (rounded<sup>1</sup>)

	Admis	sion met	hod <sup>4</sup>	Admission type <sup>4</sup>					
Group	Emergency	Elective	Other		Medical	Surgical	Other		
	%	%	%		%	%	%		
Inpatient population with diabetes	83.9	9.8	6.3		71.7	22.1	6.3		
Hypoglycaemic rescue	93.8	3.2	3.1	*	81.3	18.3	0.4	*	
• DKA	91.4	6.1	2.5	*	69.2	30.3	0.5	*	
• HHS	91.4	2.9	2.9	*	85.7	14.3	0.0	*	
Inpatient population with diabetes <sup>3</sup> (LOS≥3)	84.1	9.1	6.9		71.8	20.9	7.4		
• DFU (LOS≥3)	89.2	5.8	5.0	*	70.0	29.2	0.8	*	

### **Findings**

Table 5.4 (left) shows that higher risk characteristics for inpatient harms include:

• Emergency admission

Hypoglycaemic rescue and HHS are associated with medical admission and DKA and DFU are associated with surgical admissions.

**Notes**: \* = statistically significant at the 0.05 level vs. inpatient population. n = not statistically significant. Proportions are tested using the Chi-squared test. Cases with missing or unknown values are excluded from the calculations. The proportions of the inpatient population (data row 1, all diabetes) with missing or unknown values are: Admission method 0.0%; Admission type 0.2%. **1**. Percentages are derived from rounded values. Underlying counts between 1 and 7 are set to 5. All counts greater than 7 are rounded to the nearest 5. Consequently some percentages may not sum up to exactly 100%. **2**. Proportions and rates are calculated from the sum of nights in hospital during the period stated for people in the <u>core NDA</u>, where diabetes was diagnosed on or before admission. Day cases and same-day discharges are counted as zero days and are therefore excluded. For further information, see: <u>Further information</u>: <u>Inpatient population with diabetes</u>. **3**. See note 2 above, with additional exclusion for admissions that are less than 3 nights due to the audit requirement that new onset foot ulcers must occur more than 72 hours after admission. **4**. Admission method = The method of admission to hospital e.g. emergency or elective. An elective admission is one that has been arranged in advance. Admission type is defined by the specialty under which consultant is contracted e.g. surgical or medical. The category 'Other' covers: Admission methods 'Maternity' and 'Other'; Admission types 'Other', 'Pathology', 'Psychiatry' and 'Radiology'.

## **5. Inpatient harms: Patient profiles** Complications

#### Table 5.5: Complications during hospital admission, by inpatient harm<sup>2</sup>,

England, May 2018 - October 2021 (rounded<sup>1</sup>)

	Car	di	ovascular c (on or during a		tions <sup>4</sup>	Diabetes-specific complications <sup>4</sup> (at specified point during admission)						
Group	Angina		Myocardial infarction	Heart failure	Stroke	Admitted for DKA <sup>5, 6</sup>	Admitted <u>with</u> diabetic foot disease	RRT required <u>during</u> admission				
	%		%	%	%	%	%	%				
Inpatient population with diabetes	7.9		3.6	21.8	7.5	1.0	5.1	4.9				
Hypoglycaemic rescue	7.3	n	4.1 <mark>n</mark>	26.6 *	7.5 n	5.6 <mark>*</mark>	7.5 <mark>*</mark>	8.5 <mark>*</mark>				
• DKA	5.1	*	4.5 <mark>n</mark>	12.6 <mark>*</mark>	7.6 n	22.7 <mark>*</mark>	5.1 n	8.1 <mark>*</mark>				
• HHS	5.7	n	5.7 <mark>n</mark>	22.9 <mark>n</mark>	28.6 <mark>*</mark>	2.9 <mark>*</mark>	2.9 <mark>*</mark>	5.7 <mark>n</mark>				
Inpatient population with diabetes <sup>3</sup> (LOS≥3)	7.6		3.6	22.6	8.2	0.9	5.4	5.2				
• DFU (LOS≥3)	6.7	n	4.2 <mark>n</mark>	33.3 <mark>*</mark>	9.2 n	1.7 <mark>*</mark>	15.8 <mark>*</mark>	10.0 *				

### Findings:

Table 5.5 (left) shows that most cardiovascular or diabetes-specific complications are associated with inpatient harms.

In particular, inpatients having strokes on or during admission are more likely to experience HHS during their hospital stay.

**Notes**: \* = statistically significant at the 0.05 level (vs. inpatient population with diabetes). n = not statistically significant (vs. Inpatient population with diabetes). Proportions are tested using the Chi-squared test. **1**. Percentages are derived from rounded values. Underlying counts between 1 and 7 are set to 5. All counts greater than 7 are rounded to the nearest 5. Consequently some percentages may not sum up to exactly 100%. **2**. Proportions and rates are calculated from the sum of nights in hospital during the period stated for people in the <u>core NDA</u>, where diabetes was diagnosed on or before admission. Day cases and same-day discharges are counted as zero days and are therefore excluded. For further information, see: Further information: Inpatient population with diabetes. **3**. See note 2 above, with additional exclusion for admissions that are less than 3 nights due to the audit requirement that new onset foot ulcers must occur more than 72 hours after admission. **4**. Complication recorded at any point during the admission, except: 'Admitted for DKA' and 'Admitted with diabetes foot disease'. **5**. The definition of Admitted for DKA only includes admissions where DKA was the 1st diagnosis code on the 1st episode of the admission. The 2019 National Diabetes Inpatient Audit (NaDIA) harms audit report included cases where DKA was in any diagnosis position on the 1st episode of the hospital admission.

## National Diabetes Inpatient Safety Audit: 2018-21

## 6. Further information

## 6. Further information: NDISA harms audit linkage

To produce the patient profiles, National Diabetes Inpatient Safety Audit (NDISA) harms audit data was enriched by linkage:

#### NDISA harms audit

 Hypoglycaemic rescue • Diabetic ketoacidosis (DKA) • Hyperosmolar hyperglycaemic state (HHS) • Diabetic foot ulcer (DFU)
 Filters: Date of inpatient harm during period: May 2018 to Oct 2021

Joined on NHS number

where HES admission start/end dates overlap with date of inpatient harm

**Joined** on NHS number

#### Core National Diabetes Audit (NDA)

Age at start of NDA year<sup>1</sup>
 Sex<sup>1</sup>
 Ethnicity<sup>1</sup>
 Diabetes type<sup>1</sup>
 Diabetes duration at start of NDA year<sup>1</sup>
 Smoking status<sup>2</sup>
 Body mass index<sup>2</sup>
 Renal function<sup>2</sup>
 Deprivation quintile<sup>2</sup>
 Treatment targets<sup>3</sup>
 Care processes<sup>3</sup>

**Notes**: **1**. From the core NDA demographics table. **2**. Taking the value closest to the inpatient harm date (in corresponding NDA year or one of the preceding three years). **3**. Taking the value from the NDA year preceding the inpatient harm year (defined as Apr-Mar).

### Hospital Episode Statistics (<u>HES</u>) Admitted Patient Care (APC)

• Admission method/type

Cardiovascular complications:

Angina 
 Myocardial infarction 
 Heart failure 
 Stroke

#### **Diabetes-specific complications:**

• Required renal replacement therapy (RRT) • Admitted <u>for</u> DKA • Admitted <u>with</u> diabetic foot disease

#### Filters:

HES episode classed as finished

 Inpatient admissions only – day cases, same-day discharges and regular day/night attendances are excluded

## **6. Further information:**

## Inpatient population with diabetes

Linkage was also used to produce a comparison population of inpatients with diabetes to compare with the profile of inpatients with inpatient harms recorded:


#### **Core NDA** All years

 Sex<sup>1</sup> ● Ethnicity<sup>1</sup> ● Diabetes type<sup>1</sup> ● Diabetes duration at start of NDA year<sup>1</sup> ● Smoking status<sup>2</sup> ● Body mass index<sup>2</sup> ● Renal function<sup>2</sup> ● Deprivation quintile<sup>2</sup> ● Treatment targets<sup>3</sup> ● Care processes<sup>3</sup>

Notes: 1. From the cumulative core NDA demographics table, supplemented by the ongoing NDA 2021-22 collection. 2. Taking the value from the NDA year corresponding to the admission year.
3. Taking the value from the NDA year preceding the admission year.

#### **Comparison:** Inpatient population with diabetes Characteristics of the inpatient population, adjusted for nights in

hospital e.g. 1 night is counted once, 7 nights are counted 7 times etc.



#### HES APC 2015-16 to 2020-21 & 2021-22 (provisional)

Occupied bed days
 Admission method/type

Cardiovascular complications:

Angina 
 Myocardial infarction 
 Heart failure 
 Stroke

**Diabetes-specific complications**: • Required RRT • Admitted <u>for</u> DKA • Admitted <u>with</u> diabetic foot disease

Filters: • HES episode classed as finished

 Inpatient admissions only – day cases, same-day discharges and regular day/night attendances are excluded.

- Aged 17+ on admission.
- Diagnosed with diabetes on or before admission.
- Where compared with inpatient harm characteristics, hospital days where any inpatient harms occurred are excluded.
- Cross-HES year admissions are merged where NHS number, admission date, admission method and admission source all match.
  - Admissions are deleted if fully enveloped by another admission.

## 6. Further information: References

**Diabetes UK** Making Hospitals Safe for People with Diabetes: <u>https://www.diabetes.org.uk/professionals/resources/improving-inpatient-</u> <u>care-programme</u>

**GIRFT Programme** Getting It Right First Time: National Specialty Report: Diabetes (2020) <u>https://www.gettingitrightfirsttime.co.uk/wp-</u>content/uploads/2020/11/GIRFT-diabetes-report.pdf

**HES** Hospital Episode Statistics: <u>https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics</u>

**NaDIA** National Diabetes Inpatient Audit: <u>https://digital.nhs.uk/data-and-information/clinical-audits-and-registries/national-diabetes-inpatient-audit</u>

**NaDIA** National Diabetes Inpatient Audit, 2019 (2020) <u>https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-inpatient-audit/2019</u>

**NaDIA harms** National Diabetes Inpatient Audit - Harms: <u>https://digital.nhs.uk/data-and-information/clinical-audits-and-registries/national-diabetes-in-patient-audit-nadia-harms</u>

NaDIA harms National Diabetes Inpatient Audit – Harms, 2020 (2021) https://digital.nhs.uk/data-and-

information/publications/statistical/national-diabetes-inpatient-audit---harms/national-diabetes-inpatient-audit---harms-2020

NCEPOD (2018): Perioperative Diabetes <u>https://www.ncepod.org.uk/2018pd.html</u>

NDA National Diabetes Audit programme: <u>https://digital.nhs.uk/data-and-information/clinical-audits-and-registries/national-diabetes-audit</u> Core NDA Code National Diabetes Audit: <u>https://digital.nhs.uk/data-and-information/clinical-audits-and-registries/national-diabetes-audit/core</u> audit/core

NHS Long Term Plan (2019) <u>https://www.longtermplan.nhs.uk/publication/nhs-long-term-plan/</u>

**NHS England** Urgent and Emergency Care Daily Situation Reports 2021-22: <u>https://www.england.nhs.uk/statistics/statistical-work-areas/uec-sitrep/urgent-and-emergency-care-daily-situation-reports-2021-22/</u>

NICE NG19 Diabetic foot problems: Prevention and management <u>https://www.nice.org.uk/Guidance/NG19</u>

NICE QS6 Diabetes in adults https://www.nice.org.uk/Guidance/QS6

## 6. Further information: Acknowledgements

## The NDISA team would like to thank all the people and teams who have worked hard to contribute to this unique and valuable insight into the inpatient care of people with diabetes.

Development and delivery of NDISA is guided by a multi-professional advisory group of clinicians and experts by experience, chaired by Alistair Lumb. The NDISA Advisory Group members include:

Alistair Lumb NDISA Chair, Consultant in Diabetes and Acute General Medicine, Oxford University Hospitals Foundation Trust **Bob Young** NDA Specialist Clinical Lead Alex Berry Engagement Lead, Diabetes UK Lead Podiatrist, Oxford University Hospitals Foundation Trust Jodie Buckingham Samantha Dottin NDA Engagement Lead, Diabetes UK Principal Information Analyst, NHS Digital Kathryn Hopkins Sameeha Hussain Information Analyst, NHS Digital Information Analyst, NHS Digital Michael Mason Maureen McGinn Expert by experience Audit Manager, NHS Digital Julie Michalowski Shivani Misra Consultant Diabetologist, Imperial College Consultant Diabetologist, Ipswich Hospital & National Clinical Lead for Inpatient Diabetes **Gerry Rayman** Andrew Whitehead Audit Coordinator, NHS Digital **Arthur Yelland** Senior Information Analyst, NHS Digital

## **Prepared in collaboration with:**



## **NHS** Digital

#### **DIABETES UK** KNOW DIABETES. FIGHT DIABETES.

#### Supported by:



**The Healthcare Quality Improvement Partnership (HQIP).** The National Diabetes Inpatient Safety Audit (NDISA) is commissioned by the Healthcare Quality Improvement Partnership (HQIP) as part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP). HQIP is led by a consortium of the Academy of Medical Royal Colleges, the Royal College of Nursing, and National Voices. Its aim is to promote quality improvement in patient outcomes, and in particular, to increase the impact that clinical audit, outcome review programmes and registries have on healthcare quality in England and Wales. HQIP holds the contract to commission, manage, and develop the National Clinical Audit and Patient Outcomes Programme (NCAPOP), comprising around 40 projects covering care provided to people with a wide range of medical, surgical and mental health conditions. The programme is funded by NHS England, the Welsh Government and, with some individual projects, other devolved administrations and crown dependencies www.hgip.org.uk/national-programmes.

**NHS Digital** is the new name for the Health and Social Care Information Centre. NHS Digital managed the publication of the 2022 NDISA report.

**Diabetes UK** is the largest organisation in the UK working for people with diabetes, funding research, campaigning and helping people live with the condition.

The **National Cardiovascular Intelligence Network** (NCVIN) is a partnership of leading national cardiovascular organisations which analyses information and data and turns it into meaningful timely health intelligence for commissioners, policy makers, clinicians and health professionals to improve services and outcomes. 36



www.digital.nhs.uk @nhsdigital enquiries@nhsdigital.nhs.uk 0300 303 5678

Information and technology for better health and care

## **National Diabetes Inpatient Safety Audit**

#### Published by NHS Digital Part of the Government Statistical Service

Responsible Statistician Sally Jones, Analytical Section Head, NHS Digital

For further information <u>digital.nhs.uk</u> 0300 303 5678 <u>enquiries@nhsdigital.nhs.uk</u>

© 2022 NHS Digital. All rights reserved.

NHS Digital is the trading name of the Health and Social Care Information Centre.

This work may be re-used by NHS and government organisations without permission.